



# Pharma Newsletter



## Indian pharma industry projected to reach \$130 billion by 2030 say experts:

The Indian pharmaceutical sector, currently valued at \$55 billion, is expected to reach \$130 billion by 2030 and \$450 billion by 2047. The Indian pharmaceutical sector, a key focus area for exports, has demonstrated remarkable growth, with current market size at \$55 billion and exports contributing \$27.85 billion. The Indian pharmaceutical industry has solidified its global position as the 'Pharmacy of the World' and earned recognition as the 'Healers of the World' through its exceptional contribution to COVID-19 vaccine distribution.



## Indian pharma firms trail global peers in R&D, innovation, and talent metrics: FAST India-IIFL Securities:

The largest disparity was observed in the number of publications per billion USD revenue, with global firms producing 8.4 times more publications than Indian firms, the report noted. Global firms generated 5.6 times more patents and 8.4 times more publications per billion USD of revenue compared to Indian firms.

## Dr. Reddy's launches first-in-class drug to treat chronic constipation in India:

Dr. Reddy's Laboratories has launched Elobixibat (BixiBat) in India, a first-in-class drug for chronic constipation, after receiving CDSCO approval following successful Phase-3 trials. It is the first company to launch Elobixibat in India.

## Toripalimab to fortify Dr. Reddy's oncology portfolio in India:

Dr. Reddy's Laboratories has launched Zytorvi (toripalimab), a PD-1 inhibitor for recurrent or metastatic nasopharyngeal carcinoma, in collaboration with Shanghai Junshi Biosciences. This positions Dr. Reddy's as a leader in oncology innovation in India.

## Lupin acquires three trademarks from Boehringer Ingelheim to strengthen diabetes portfolio in India:

Lupin Limited has acquired anti-diabetes trademarks GIBTULIO, GIBTULIO MET, and AJADUO from Boehringer Ingelheim to enhance its diabetes portfolio in India. The trademark transfer will be completed by March next year.

## Aster DM Healthcare-Quality Care India merger talks enter final lap:

Merger talks between Blackstone-owned Quality Care India and Aster DM Healthcare are nearing completion, with Blackstone set to hold a majority stake in the new entity, Aster DM Quality CARE. TPG and Aster's promoters, the Moopen family, will hold minority stakes. The Moopen family had previously separated its West Asia hospital chain into a separate entity.

## **AIIMS and Wipro GE Healthcare Sign MoU to Establish 'AI Health Innovations Hub' in New Delhi:**

AIIMS New Delhi and Wipro GE Healthcare have signed an MoU to create the AI Health Innovations Hub, aiming to integrate AI into cardiology, oncology, and neurology. The partnership will focus on improving diagnostic accuracy, treatment protocols, and patient data tracking. Wipro GE will invest \$1 Mn over five years to co-develop AI-driven healthcare solutions, with AIIMS providing clinical expertise.

## **CD&R makes \$3.3 Mn open offer for 26% stake in Sanofi Consumer Healthcare India:**

Clayton, Dubilier & Rice (CD&R) has launched an open offer to acquire a 26% stake in Sanofi Consumer Healthcare India for up to \$3.3 Mn. The offer price is \$5.8 Mn per share, with CD&R targeting 60.4% of voting rights after the deal.

# **Hospital Sector**

## **India now has some of the most advanced hospitals in the world:**

India has become a global leader in healthcare innovation, offering advanced hospitals with cutting-edge technology and world-class care. With prestigious accreditations like JCI and NABH, these facilities ensure top standards in safety and efficiency. Major hubs for medical tourism include Delhi, Chennai, and Mumbai, with some patients also visiting Bangalore and Kolkata. Online platforms like Fly Hospital help

## **Cipla introduces AI-powered mobile application for asthma screening in India :**

Cipla has launched CipAir, a mobile app for first-line asthma screening in India. Clinically validated through a pan-India study, the app helps users assess their likelihood of an asthma diagnosis, enabling timely intervention and better early detection and care.

international patients make informed choices for safe and effective treatment.

Hospitals garner 50% share in healthcare FDI In FY24, hospitals in India led foreign direct investment (FDI) in healthcare, accounting for 50% of total FDI (\$1.5 Bn), a significant rise from 24% in FY21. This shift highlights growing investor interest in hospitals alongside the pharmaceutical sector.

**Apollo Hospitals Announces \$6.1 Bn Expansion Plan to Add 3,500 Beds Across India by FY26:** Apollo Hospitals plans a \$6.1 crore expansion to add 3,500+ beds across 11 locations by FY26. This includes greenfield, brownfield, and acquisition projects to strengthen its presence in key urban areas, with \$1.9 Mn already allocated for land and initial costs.

**Monash's clinical AI collab with India's Apollo Hospitals and more briefs:** Monash University has partnered with Apollo Hospitals to test and validate clinical AI, using de-identified health data from over 200 Mn patients. The collaboration aims to advance digital health research and train AI algorithms for detecting diseases like cancer, heart disease, and diabetes.



ECHS Adds 40 Private Hospitals and Diagnostic Centres to Network, Expands Healthcare Access for Veterans: ECHS expands healthcare access for veterans by empaneling 40 private hospitals, nursing homes, and diagnostic centers nationwide. Finalized during the 69th Screening Committee Meeting in May 2024, the move ensures quality medical care at CGHS rates, adhering to Ministry of Defence guidelines.

Aster DM Healthcare and Quality Care India Announce Landmark Merger to Form One of India's Top 3 Hospital Chains: Aster DM Healthcare and Quality Care India (Care Plus KIMSHealth), backed by Blackstone and TPG, have finalized a merger, creating one of India's top three hospital chains. The new entity will be jointly controlled by Aster's promoters (24%) and Blackstone (30.07%). The merger values Aster at 36.6x FY24 adjusted post IND-AS EV/EBITDA, underscoring the growing appeal of India's healthcare sector to global investors.

Aster DM Healthcare to Fully Acquire Aster Aadhar Hospital: Aster DM Healthcare will fully acquire Aster Aadhar Hospital, Kolhapur, by

December 2025, as part of its growth strategy. The company targets an 18%-20% CAGR for its Indian operations from FY25 to FY29 and expects its Operating EBITDA margin to rise to 23%-25% over the next five years.

Fortis Healthcare gets CCI nod to acquire stake in Agilus Diagnostics: The Competition Commission of India (CCI) has approved Fortis Healthcare's acquisition of an additional 31.52% stake in Agilus Diagnostics. This acquisition strengthens Fortis's diagnostics services, enhancing its presence in the sector.

Yatharth Hospital Expands Presence in North India with Second Acquisition of 2024: Yatharth Hospital & Trauma Care Services has acquired a renowned super-specialty hospital in Model Town, New Delhi, marking its second acquisition this year. Following its acquisition of Asian Fidelis Hospital in Faridabad, this move expands Yatharth's presence in North India. The acquired hospital, which has over 300 beds and offers a wide range of services, strengthens Yatharth's position in the Delhi market.

## Med Devices:

### Catalyzing India's Medical Device Revolution:

India's healthcare sector is set for transformation with the Strengthening of Medical Device Industry (SMDI) scheme by

the Department of Pharmaceuticals (DoP). With a ₹500 crore outlay from FY 2024-25 to FY 2026-27, the initiative aims to establish India as a global leader in medical devices by boosting domestic manufacturing, creating advanced testing facilities, enhancing skills through specialized training, and supporting clinical studies for safety and efficacy. This effort aligns with India's goal to reduce import dependence and foster innovation, driving self-reliance in critical healthcare technologies.



For further conversations, please reach out to us at  
**[info@kraftlandconsults.com](mailto:info@kraftlandconsults.com)**